Tipping the balance for the primary prevention of breast cancer.
Victor G
VG
Vogel
D000328:Adult; D000367:Age Factors; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000453:epidemiology / Q000378:metabolism / Q000517:prevention & control*; D015986:Confounding Factors, Epidemiologic; D004958:Estradiol / Q000097:blood; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications*; D011322:Primary Prevention / Q000379:methods; D011759:Pyrrolidines / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D018570:Risk Assessment; D018401:Sample Size; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D016588:Anticarcinogenic Agents; D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D011759:Pyrrolidines; D020845:Selective Estrogen Receptor Modulators; D013764:Tetrahydronaphthalenes; C111332:Lasofoxifene; D020849:Raloxifene Hydrochloride; D004958:Estradiol